Trial · NCT04296838
Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF
NCT04296838, Phase 2, Phase 3, Terminated, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF. Trials, record NCT04296838. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04296838
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF
- NCT number
- NCT04296838
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 5 participants, actual
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Uveitis, Macular Edema, Vascular Endothelial Growth Factor, Effect of Drugs
- Interventions
- intravitreal injection of Conbercept
- First posted
- 2020-03-05
- Last updated
- 2022-10-25
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes of best corrected visual acuity (BCVA) | baseline and at 1, 2, 3, 4, 5, 6 months after injection | changes from baseline BCVA at 1, 2, 3, 4, 5, 6 months after injection (at each follow-up visit) |
| Primary | Changes of central retinal thickness (CRT) | baseline and at 1, 2, 3, 4, 5, 6 months after injection | changes from baseline CRT at 1, 2, 3, 4, 5, 6 months after injection (at each follow-up visit) |
| Secondary | changes of concentration of inflammatory cytokines | before injection (baseline), 1 month after the first injection, at the end of the study (6 months) | inflammatory cytokines include VEGF-A, VEGF-B, interleukin (IL)-2, interleukin-6, interleukin-8, interleukin-10, interleukin-12, tumor necrosis factor (TNF) α, monocyte chemotactic protein-1 and macrophage inflammatory protein-1 |
| Secondary | inflammatory status | baseline and at 1, 2, 3, 4, 5, 6 months after injection | changes from baseline flare and cells in the anterior chamber at 1, 2, 3, 4, 5, 6 months after injection |
| Secondary | side effects of the eye: increase of intraocular pressure | baseline and at 1, 2, 3, 4, 5, 6 months after injection | changes from baseline intraocular pressure at 1, 2, 3, 4, 5, 6 months after injection |
| Secondary | side effects of the eye: development/exacerbation of cataract | baseline and at 1, 2, 3, 4, 5, 6 months after injection | whether cataract is developed or exacerbated |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04296838
GET https://conductscience.org/api/trials/v1/NCT04296838/registered